Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
BioXcel Therapeutics, Inc. (BTAI)
|
Add to portfolio |
|
|
|
| Price: |
$22.32
| | Metrics |
| OS: |
29.3
|
M
| |
|
|
| Market cap: |
$653
|
M
| |
|
|
|
|
|
| |
|
|
|
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
|
|
| |
|
|
|
|
|
| |
|
|
| EPS |
($3.33)
| |
|
|
|
BVPS
|
$0.20
| |
111.40
|
x P/B
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Gross profit | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Gross margin | 94.7% | | | | | | |
| Selling, general and administrative | 68.8 | | | | | | |
| Research and development | 91.2 | 52.7 | 58.0 | 25.8 | 14.6 | 2.7 | |
| General and administrative | | 54.2 | 24.3 | 7.8 | 5.4 | 1.8 | |
| EBIT | -159.6 | -106.9 | -82.3 | -33.6 | -20.0 | -4.5 | |
| EBIT margin | -42572.0% | | | | | | |
| Pre-tax income | 0.0 | -106.9 | -82.2 | -33.0 | -19.3 | -4.5 | |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net income | 0.0 | -106.9 | -82.2 | -33.0 | -19.3 | -4.5 | |
| Net margin | 0.0% | | | | | | |
| |
| Diluted EPS | $0.00 | ($4.05) | ($3.79) | ($2.02) | ($1.32) | ($0.47) | |
| Shares outstanding (diluted) | 28.0 | 26.4 | 21.7 | 16.3 | 14.6 | 9.7 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|